Randomized Clinical Trial of High-Dose Rifampicin With or Without Levofloxacin Versus Standard of Care for Pediatric Tuberculous Meningitis: The TBM-KIDS Trial
Author:
Paradkar Mandar S12, Devaleenal D Bella3, Mvalo Tisungane45, Arenivas Ana6, Thakur Kiran T7, Wolf Lisa8, Nimkar Smita12, Inamdar Sadaf12, Giridharan Prathiksha3, Selladurai Elilarasi9, Kinikar Aarti110, Valvi Chhaya110, Khwaja Saltanat12, Gadama Daphne4, Balaji Sarath3, Yadav Kattagoni Krishna3, Venkatesan Mythily3, Savic Radojka11, Swaminathan Soumya12, Gupta Amita8ORCID, Gupte Nikhil128, Mave Vidya128, Dooley Kelly E8, Agiwal Shivali, Ahire Rupali, Balasubramanian Usha, Bendre Manjushree, Chandane Jyoti, Chopade Kavita, Dalimbkar Shamala, Deshpande Prasad, Dhage Rajendra, Ithape Mahesh, Jadhav Varsha, Kante Sonali, Kapre Pallavi, Khan Nawshaba, Kulkarni Vandana, Madewar Renu, Meshram Shashibhushan, Muttha Kunal, Nadgeri Vaishali, Nagargoje Arti, Nagraj Amita, Nijampurkar Aparna, Onawale Prerana, Pawar Namrata, Pawar Prashant, Pradhan Neeta, Shaikh Varsha, Shaikh Zaheda, Shere Dhananjay, Wani Gouri, Kulkarni Rajesh, Rajput Uday, Ganesan Mangalambal, Arasan Gunasundari, Shankar Shakila, Mary S Stella, Karuppaiah Sureshwari, Pauline Leema, Karunakaran Pramila Snegha, Arul Priyadharshini, Ganesh Sankar, Hanna Luke Elizabeth, Ramesh K, Kannan M, Vijayakumar Ruthra, Sivakumar Surekha S, Devika K, Radhakrishnan A, Preethi A R, Rajkumar S, Saravanan N, Ramachandran Geetha, Hemanth Kumar A K, Dharman M, Sudha V, Hissar Syed, Nagarajan Valarmathi, Jennifer Linda, Supriya R, Manimegalai R, Kandan Santhanam, Maniselvi Archana, Puspha Oli, Vaishnavi S, Selvi R, Neelakandan Logeswari, Chiunda Mary, Chunga Moreen, Kamanga Madalo, Kamthunzi Portia, Kanthiti Elizabeth, Mbewe Abineli, Msiska Emmie, Mumba Noel, Zifa Phiri Ian, Palichina Victor, Sichali Dorothy, Rexroad Vivian, Hesseling Anneke, Gupta Y K, Phillips Patrick,
Affiliation:
1. BJ Government Medical College–Johns Hopkins Clinical Research Site , Pune , India 2. Johns Hopkins India , Pune , India 3. Department of Clinical Research, Indian Council of Medical Research–National Institute for Research in Tuberculosis , Chennai , India 4. UNC Project Malawi , Lilongwe , Malawi 5. Department of Pediatrics, School of Medicine, University of North Carolina at Chapel Hill , Chapel Hill, North Carolina , USA 6. Section of Neuropsychology, Neurological Institute, Cleveland Clinic Foundation , Cleveland, Ohio , USA 7. Department of Neurology, Columbia University Irving Medical Center/New York Presbyterian Hospital , New York, New York , USA 8. Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA 9. Institute of Child Health and Hospital for Children , Chennai , India 10. Department of Pediatrics, BJ Government Medical College , Pune , India 11. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco , San Francisco, California , USA 12. World Health Organization , Geneva , Switzerland
Abstract
Abstract
Background
Pediatric tuberculous meningitis (TBM) commonly causes death or disability. In adults, high-dose rifampicin may reduce mortality. The role of fluoroquinolones remains unclear. There have been no antimicrobial treatment trials for pediatric TBM.
Methods
TBM-KIDS was a phase 2 open-label randomized trial among children with TBM in India and Malawi. Participants received isoniazid and pyrazinamide plus: (i) high-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, arm 1); (ii) high-dose rifampicin and levofloxacin (R30HZL, arm 2); or (iii) standard-dose rifampicin and ethambutol (R15HZE, arm 3) for 8 weeks, followed by 10 months of standard treatment. Functional and neurocognitive outcomes were measured longitudinally using Modified Rankin Scale (MRS) and Mullen Scales of Early Learning (MSEL).
Results
Of 2487 children prescreened, 79 were screened and 37 enrolled. Median age was 72 months; 49%, 43%, and 8% had stage I, II, and III disease, respectively. Grade 3 or higher adverse events occurred in 58%, 55%, and 36% of children in arms 1, 2, and 3, with 1 death (arm 1) and 6 early treatment discontinuations (4 in arm 1, 1 each in arms 2 and 3). By week 8, all children recovered to MRS score of 0 or 1. Average MSEL scores were significantly better in arm 1 than arm 3 in fine motor, receptive language, and expressive language domains (P < .01).
Conclusions
In a pediatric TBM trial, functional outcomes were excellent overall. The trend toward higher frequency of adverse events but better neurocognitive outcomes in children receiving high-dose rifampicin requires confirmation in a larger trial.
Clinical Trials Registration
NCT02958709.
Funder
Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health National Institute of Allergy and Infectious Diseases
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Microbiology (medical)
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|